Study Summary
This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.
Interested in this trial?
Submit an InquiryInterventions
CD19 CAR-T cellsBIOLOGICAL
A single infusion of CD19-CAR-T cells will be administered intravenously.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Chongqing University Cancer Hospital | Chongqing | Chongqing Municipality | China |